The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
© 2024 TheOutpost.AI All rights reserved
Curated by THEOUTPOST
On August 31, 2024
2 Sources
[1]
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MacroGenics, CrowdStrike, Vicor, and American Airlines and Encourages Investors to Contact the Firm - CrowdStrike Holdings (NASDAQ:CRWD), American Airlines Gr (NASDAQ:AAL)
NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of MacroGenics, Inc. MGNX, CrowdStrike Holdings, Inc. CRWD, Vicor Corporation VICR, and American Airlines Group Inc. AAL. Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. MacroGenics, Inc. MGNX Class Period: March 7, 2024 - May 9, 2024 Lead Plaintiff Deadline: September 24, 2024 On May 9, 2024, MacroGenics announced in a press release that a total of five fatal outcomes had occurred in its TAMARACK Phase 2 study of vobramitamab duocarmazine in patients with metastatic castration resistant prostate cancer. On this news, the price of MacroGenics shares declined by $11.36 per share, or approximately 77.4%, from $14.67 per share on May 9, 2024 to close at $3.31 on May 10, 2024. The lawsuit alleges that the Company made material misrepresentations by providing overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts related to early interim safety data results from the TAMARACK Phase 2 study. For more information on the MacroGenics class action go to: https://bespc.com/cases/MGNX CrowdStrike Holdings, Inc. CRWD Class Period: November 29, 2023 - July 29, 2024 Lead Plaintiff Deadline: September 30, 2024 CrowdStrike is a global cybersecurity company that provides software that helps prevent data breaches. According to the complaint, CrowdStrike's main product is the Falcon software platform, which purportedly uses artificial intelligence and machine learning technologies to detect, prevent, and respond to security breach threats. The CrowdStrike class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) CrowdStrike had instituted deficient controls in its procedure for updating Falcon and was not properly testing updates to Falcon before rolling them out to customers; (ii) this inadequate software testing created a substantial risk that an update to Falcon could cause major outages for a significant number of CrowdStrike's customers; and (iii) such outages could pose, and in fact ultimately created, substantial reputational harm and legal risk to CrowdStrike. The CrowdStrike class action lawsuit further alleges that on July 19, 2024, news broke that a flawed Falcon content update caused major worldwide technology outages for millions of devices running Microsoft Windows. On this news, the price of CrowdStrike stock fell more than 11%, according to the complaint. Then, on July 22, 2024, the CrowdStrike class action lawsuit further alleges that Congress called on CrowdStrike CEO, defendant George Kurtz, to testify regarding the crisis and CrowdStrike's stock rating was downgraded by analysts such as Guggenheim and BTIG. On this news, the price of CrowdStrike stock fell more than 13%, according to the complaint. Finally, on July 29, 2024, news outlets reported that Delta Air Lines had hired prominent attorney David Boies to seek damages from CrowdStrike following the software outage, according to the complaint. On this news, the price of CrowdStrike stock fell nearly 10%, according to the CrowdStrike class action lawsuit. For more information on the CrowdStrike class action go to: https://bespc.com/cases/CRWD Vicor Corporation VICR Class Period: April 26, 2023 - February 22, 2024 Lead Plaintiff Deadline: September 23, 2024 According to the complaint, during the class period, Defendants created the false and/or materially misleading impression that Vicor had secured a significant deal for its H100 product that, according to analysts, was Nvidia Corporation. These statements proved incorrect when first, on October 24, 2023, Vicor conspicuously failed to discuss the deal and then later, on February 22, 2024, when the Company issued a press release announcing its end of year earnings and flagged a sharp reversal in new contracts and sales. From an intra-class period high of nearly $100/share, Vicor's stock price has fallen approximately 60%. For more information on the Vicor class action go to: https://bespc.com/cases/VICR American Airlines Group Inc. AAL Class Period: January 25, 2024 - May 28, 2024 Lead Plaintiff Deadline: September 16, 2024 On May 28, 2024, after the market closed, American Airlines announced that its Chief Commercial Officer was departing. Additionally, the Company disclosed that it was lowering its guidance. In an industry conference the following day, May 29, 2024, the Company's CEO stated that the Company's "expectation for domestic performance has worsened materially since [it] provided guidance in April," and that the revision "is largely due to a softer domestic environment than [the Company was] expecting and [its] performance within that environment." On this news, American Airlines' stock price fell $1.82, or 13.5%, to close at $11.62 per share on May 29, 2024, thereby injuring investors. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company's reports of growth relied far too heavily on inflated demand assumptions allegedly stemming from the implemented changes to their sale and distribution strategy which had downsized the Company's sales and distribution channels to redirect consumers solely to their online platform; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. For more information on the American Airlines class action go to: https://bespc.com/cases/AAL About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648 investigations@bespc.com www.bespc.com Market News and Data brought to you by Benzinga APIs
[2]
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm - Extreme Networks (NASDAQ:EXTR), Sprinklr (NYSE:CXM)
NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Moderna, Inc. MRNA, PDD Holdings Inc. PDD, Extreme Networks, Inc. EXTR, and Sprinklr, Inc. CXM. Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Moderna, Inc. MRNA Class Period: January 18, 2023 - June 25, 2024 Lead Plaintiff Deadline: October 8, 2024 The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) mRNA-1345 was less effective than Defendants had led investors to believe; (2) accordingly, mRNA-1345's clinical and/or commercial prospects were overstated; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times. For more information on the Moderna class action go to: https://bespc.com/cases/MRNA PDD Holdings Inc. PDD Class Period: April 30, 2021 - June 25, 2024 Lead Plaintiff Deadline: October 15, 2024 According to the complaint, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose, among other things, that: (1) PDD Holdings' applications contained malware, which was designed to obtain user data without the user's consent, including reading private text messages; (2) PDD Holdings has no meaningful system to prevent goods made by forced labor from being sold on its platform, and has openly sold banned products on its Temu platform; (3) the foregoing subjected PDD Holdings to a heightened risk of legal and political scrutiny; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. For more information on the PDD Holdings class action go to: https://bespc.com/cases/PDD Extreme Networks, Inc. EXTR Class Period: July 27, 2022 - January 30, 2024 Lead Plaintiff Deadline: October 15, 2024 The Complaint alleges that throughout the class period, Defendants made false and misleading statements to the market. Specifically, the Complaint alleges that: (1) Extreme Networks suffered from weak client demand trends due to customers ordering more product than necessary in the wake of the COVID-19 pandemic; (2) the Company attempted to offset the negative organic demand trends with backlog orders exceeding the proportion it represented to investors; (3) based on these facts, the Company's public statements were false and materially misleading throughout the class period; and (4) when the market learned the truth about Extreme Networks, investors suffered damages. For more information on the Extreme Networks class action go to: https://bespc.com/cases/EXTR Sprinklr, Inc. CXM Class Period: March 29, 2023 - June 5, 2024 Lead Plaintiff Deadline: October 14, 2024 According to the complaint, on December 6, 2023, Sprinklr announced strong 3Q 2024 results and then reduced its estimated growth for the 4Q and full year 2025. The Company blamed it on "subscription renewal pressures" caused by macro headwinds and the "over-rotation" of sales to its Contact Center as a Service ("CCaaS") market. On an earnings call in September 2023, CEO Ragy Thomas stated that the Company's investments in AI and the CCaaS opportunity were main contributors to its customer growth. Subsequently, in March several changes were made to the Company's C-level positions. Analysts commenting on the reduced estimates mention surprise at the timing and shift in the Company's sales strategy. Following this news, Sprinklr's stock price fell by $5.59 per share, or approximately 34% to close at $11.11 per share. On June 5, 2024, Sprinklr again announced significantly reduced growth expectations, this time cutting fiscal year 2025 projections another three percent, down to a mere 7% annual growth, again attributing the losses to reduced customer retention in Sprinklr's core business and macro headwinds. The price of Sprinklr's common stock declined dramatically. From a closing market price of $10.84 per share on June 5, 2024 Sprinklr's stock price fell to $9.20 per share on June 6, 2024, a decline of more than 15% in the span of one day. For more information on the Sprinklr class action go to: https://bespc.com/cases/CXM About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Marion Passmore, Esq. (212) 355-4648 investigations@bespc.com www.bespc.com Market News and Data brought to you by Benzinga APIs
Share
Share
Copy Link
Law firm Bragar Eagel & Squire, P.C. announces class action lawsuits against Macrogenics, Inc. and Moderna, Inc. Investors are urged to contact the firm for more information about their rights and potential recovery.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, has announced that class action lawsuits have been filed on behalf of shareholders of multiple companies, including Macrogenics, Inc. and Moderna, Inc. These legal actions highlight potential violations of federal securities laws, putting investors on alert [1][2].
The class action lawsuit against Macrogenics, Inc. (NASDAQ: MGNX) is filed on behalf of individuals who purchased or acquired securities between February 15, 2023 and May 18, 2023. The lawsuit alleges that the company made materially false and misleading statements regarding its business, operations, and prospects [1].
Similarly, a class action lawsuit has been initiated against Moderna, Inc. (NASDAQ: MRNA) for shareholders who purchased or acquired securities between March 22, 2023 and April 4, 2023. The complaint accuses Moderna of making false and misleading statements about its business, operations, and compliance policies [2].
These lawsuits have significant implications for investors who held securities in these companies during the specified periods. Shareholders may have the opportunity to recover damages and are encouraged to seek more information about their legal rights and potential recovery options [1][2].
Bragar Eagel & Squire, P.C., with offices in New York and California, is spearheading these legal actions. The firm specializes in representing individual and institutional investors in complex litigation, including securities fraud and fiduciary duty matters [1][2].
Investors who purchased or acquired securities in Macrogenics, Inc. or Moderna, Inc. during the class periods are advised to contact the firm. Bragar Eagel & Squire, P.C. offers free case evaluations to help shareholders understand their rights and options [1][2].
These lawsuits are part of a broader trend in securities litigation, where companies face legal challenges for alleged misrepresentations or omissions that may have affected stock prices. Such actions aim to protect investor interests and promote transparency in financial markets [1][2].
For more information about these class action lawsuits or to discuss potential claims, shareholders are encouraged to visit Bragar Eagel & Squire, P.C.'s website or contact the firm directly. The firm's attorneys are available to address any questions or concerns investors may have regarding their rights and potential recovery in these cases [1][2].
Reference
Bragar Eagel & Squire, P.C. announces class action lawsuits against several companies including Symbotic Inc., Infinity Pharmaceuticals, Inc., and Enviva Inc. The law firm urges affected investors to join the suits before upcoming deadlines.
2 Sources
Multiple law firms have announced class action lawsuits against tech companies including CrowdStrike Holdings, Inc. and DXC Technology Company. These lawsuits allege violations of federal securities laws, with deadlines approaching for affected investors to seek lead plaintiff status.
2 Sources
Law firms remind investors of upcoming deadlines for class action lawsuits against CAE Inc., American Airlines Group Inc., Oddity Tech Ltd., and Lifecore Biomedical, Inc. These cases allege violations of securities laws, urging affected shareholders to take action.
2 Sources
Law firms remind investors of upcoming deadlines for class action lawsuits against CAE Inc., American Airlines Group Inc., Oddity Tech Ltd., and Lifecore Biomedical, Inc. These cases allege violations of securities laws, urging affected shareholders to take action.
2 Sources
Multiple law firms have announced class action lawsuits against CrowdStrike Holdings, Inc., alleging violations of federal securities laws. The lawsuits claim that the company made false and misleading statements about its business prospects and financial performance.
2 Sources